دورية أكاديمية
Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results.
العنوان: | Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results. |
---|---|
المؤلفون: | Christlieb SB; Department of Nuclear Medicine, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark. sofie.christlieb@gmail.com., Strandholdt CN; Department of Nuclear Medicine, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Olsen BB; Department of Nuclear Medicine, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Mylam KJ; Department of Haematology, Vejle Hospital, Kabbeltoft 25, 7100, Vejle, Denmark., Larsen TS; Department of Haematology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Nielsen AL; Department of Nuclear Medicine, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Rohde M; Department of Ear, Nose and Throat, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Gerke O; Department of Nuclear Medicine, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Olsen KE; Department of Pathology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Møller MB; Department of Pathology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Kristensen BW; Department of Pathology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Abildgaard N; Department of Haematology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark., Alavi A; Hospital of the University of Pennsylvania, 3400 Spruce St., Philadelphia, PA, 19104, USA., Høilund-Carlsen PF; Department of Nuclear Medicine, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark. |
المصدر: | European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2016 Sep; Vol. 43 (10), pp. 1824-36. Date of Electronic Publication: 2016 Apr 22. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Berlin : Springer-Verlag Berlin, 2002- |
مواضيع طبية MeSH: | Fluorodeoxyglucose F18/*pharmacokinetics , Glucose-6-Phosphatase/*metabolism , Hexokinase/*metabolism , Lymphoma/*diagnostic imaging , Lymphoma/*metabolism , Positron Emission Tomography Computed Tomography/*methods, Adolescent ; Adult ; Aged ; Algorithms ; Diagnosis, Differential ; Female ; Humans ; Image Enhancement/methods ; Image Interpretation, Computer-Assisted/methods ; Male ; Middle Aged ; Pilot Projects ; Reproducibility of Results ; Sensitivity and Specificity ; Tumor Burden ; Young Adult |
مستخلص: | Purpose: The purpose of this study was to determine the ability of dual time-point (DTP) PET/CT with (18)F-FDG to discriminate between malignant and benign lymphadenopathies. The relationship between DTP FDG uptake and glucose metabolism/hypoxia markers in lymphadenopathies was also assessed. Methods: Patients with suspected lymphoma or recently diagnosed treatment-naive lymphoma were prospectively enrolled for DTP FDG PET/CT (scans 60 min and 180 min after FDG administration). FDG-avid nodal lesions were segmented to yield volume and standardized uptake values (SUV), including SUVmax, SUVmean, cSUVmean (with partial volume correction), total lesion glycolysis (TLG) and cTLG (with partial volume correction). Expression of glucose transporter-1 (GLUT-1), hexokinase-II (HK-II), glucose-6-phosphatase (G6Pase) and hypoxia-inducible factor-1alpha (HIF-1alpha) were assessed with immunohistochemistry and enzyme activity was determined for HK and G6Pase. Results: FDG uptake was assessed in 203 lesions (146 malignant and 57 benign). Besides volume, there were significant increases over time for all parameters, with generally higher levels in the malignant lesions. The retention index (RI) was not able to discriminate between malignant and benign lesions. Volume, SUVmax, TLG and cTLG for both scans were able to discriminate between the two groups statistically, but without complete separation. Glucose metabolism/hypoxia markers were assessed in 15 lesions. TLG and cTLG were correlated with GLUT-1 expression on the 60-min scan. RI-max and RI-mean and SUVmax, SUVmean and cSUVmean on the 60-min scan were significantly correlated with HK-II expression. Conclusion: RI was not able to discriminate between malignant and benign lesions, but some of the SUVs were able to discriminate on the 60-min and 180-min scans. Furthermore, FDG uptake was correlated with GLUT-1 and HK-II expression. |
References: | J Biol Chem. 1953 Jun;202(2):675-85. (PMID: 13061491) Ann Nucl Med. 2003 Jun;17 (4):327-31. (PMID: 12932118) Int J Hematol. 2013 Jan;97(1):43-9. (PMID: 23212465) Eur J Nucl Med. 1999 Oct;26(10 ):1345-8. (PMID: 10541835) Nucl Med Mol Imaging. 2014 Sep;48(3):187-95. (PMID: 25177375) J Clin Oncol. 2014 Sep 20;32(27):3059-68. (PMID: 25113753) Leuk Lymphoma. 2012 Oct;53(10 ):1876-81. (PMID: 22432519) Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1158-70. (PMID: 21225422) J Nucl Med. 2009 May;50 Suppl 1:11S-20S. (PMID: 19380405) Mol Clin Oncol. 2014 Jul;2(4):525-529. (PMID: 24940488) Br J Haematol. 1992 Jan;80(1):21-6. (PMID: 1536807) Oncol Res. 2009;17 (7):331-7. (PMID: 19408578) Q J Nucl Med Mol Imaging. 2009 Feb;53(1):9-19. (PMID: 18337683) Leuk Lymphoma. 2014 Mar;55(3):520-5. (PMID: 23701133) Hell J Nucl Med. 2011 Jan-Apr;14 (1):8-14. (PMID: 21512658) Ann Nucl Med. 2012 Oct;26(8):616-21. (PMID: 22692457) Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Apr;113(4):464-71. (PMID: 22676927) Biotherapy. 1998;10(4):309-20. (PMID: 9592019) Radiother Oncol. 2013 Jul;108(1):86-90. (PMID: 23618503) J Nucl Med. 1978 Oct;19(10):1154-61. (PMID: 214528) Acta Biochim Pol. 2004;51(3):563-85. (PMID: 15448722) J Int Med Res. 2010;38(6):2160-8. (PMID: 21227022) Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54. (PMID: 25452219) Mol Imaging Biol. 2013 Jun;15(3):345-52. (PMID: 23090853) Ann Nucl Med. 2013 Feb;27(2):163-9. (PMID: 23188388) J Nucl Med. 2002 Feb;43(2):173-80. (PMID: 11850481) Anal Biochem. 1976 May 7;72:248-54. (PMID: 942051) Ann N Y Acad Sci. 2011 Jun;1228:1-18. (PMID: 21718318) Nucl Med Biol. 1998 May;25(4):317-22. (PMID: 9639291) J Nucl Med. 2012 Jul;53(7):1041-7. (PMID: 22627001) Eur J Nucl Med Mol Imaging. 2013 May;40(5):779-87. (PMID: 23361859) Nucl Med Biol. 2009 Feb;36(2):191-7. (PMID: 19217531) Semin Nucl Med. 1998 Oct;28(4):352-8. (PMID: 9800240) Nucl Med Commun. 2009 Aug;30(8):594-601. (PMID: 19536037) J Nucl Med. 2001 Sep;42(9):1412-7. (PMID: 11535734) |
فهرسة مساهمة: | Keywords: Dual time-point FDG PET/CT; Glucose transporter-1; Glucose-6-phosphatase; Hexokinase; Hypoxia-inducible factor-1alpha; Lymphadenopathies |
المشرفين على المادة: | 0Z5B2CJX4D (Fluorodeoxyglucose F18) EC 2.7.1.1 (Hexokinase) EC 3.1.3.9 (Glucose-6-Phosphatase) |
تواريخ الأحداث: | Date Created: 20160423 Date Completed: 20170222 Latest Revision: 20181113 |
رمز التحديث: | 20240628 |
DOI: | 10.1007/s00259-016-3385-6 |
PMID: | 27102266 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!